Alberto Tejedor Selected Research

Cilastatin

9/2020	Nephroprotective Effect of Cilastatin against Gentamicin-Induced Renal Injury In Vitro and In Vivo without Altering Its Bactericidal Efficiency.
10/2017	Cisplatin-induced renal inflammation is ameliorated by cilastatin nephroprotection.
1/2015	Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity.
9/2012	Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats.
8/2010	Cilastatin attenuates cisplatin-induced proximal tubular cell damage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alberto Tejedor Research Topics

Disease

8	Acute Kidney Injury (Acute Renal Failure) 09/2020 - 08/2010
3	Inappropriate ADH Syndrome (SIADH) 01/2014 - 03/2012
3	Neoplasms (Cancer) 09/2013 - 08/2010
3	Chronic Obstructive Pulmonary Disease (COPD) 09/2012 - 06/2009
2	Hypoxia (Hypoxemia) 01/2020 - 06/2015
2	Hyponatremia 01/2014 - 12/2013
1	Water Intoxication 06/2022
1	Disease Progression 01/2020
1	COVID-19 01/2020
1	Hyperkalemia 01/2019
1	Fibrosis (Cirrhosis) 01/2019
1	Kidney Diseases (Kidney Disease) 01/2018
1	Pulmonary Aspergillosis 01/2018
1	Chronic Renal Insufficiency 01/2018
1	Inflammation (Inflammations) 10/2017
1	Necrosis 01/2015
1	Infections 01/2015
1	Cachexia 09/2013
1	Wasting Syndrome (Wasting Disease) 03/2012
1	Type 2 Diabetes Mellitus (MODY) 01/2011
1	Lactic Acidosis 01/2011
1	Ischemia 01/2009

Drug/Important Bio-Agent (IBA)

6	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 08/2010
5	Cilastatin FDA Link 09/2020 - 08/2010
3	Oxygen (Dioxygen)IBA 01/2020 - 02/2011
3	Vasopressins (Vasopressin)IBA 01/2014 - 03/2012
2	Furosemide (Lasix)FDA LinkGeneric 01/2014 - 12/2013
2	Tolvaptan FDA Link 01/2014 - 12/2013
1	ElectrolytesIBA 06/2022
1	Indicators and Reagents (Reagents)IBA 05/2019
1	CytokinesIBA 05/2019
1	Interleukin-6 (Interleukin 6)IBA 05/2019
1	SodiumIBA 01/2019
1	PotassiumIBA 01/2019
1	Sodium Channels (Sodium Channel)IBA 01/2019
1	Vitamin K FDA Link 01/2018
1	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2018
1	deoxycholate drug combination amphotericin BIBA 01/2018
1	Butyrates (Butyrate)IBA 01/2018
1	Uremic ToxinsIBA 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 06/2015
1	HexokinaseIBA 06/2015
1	Phosphofructokinase-2 (Phosphofructokinase 2)IBA 06/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2015
1	Vancomycin FDA LinkGeneric 01/2015
1	Proteasome Endopeptidase Complex (Proteasome)IBA 09/2013
1	Electron Transport Complex III (Coenzyme Q-Cytochrome-c Reductase)IBA 09/2012
1	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2012
1	SaltsIBA 03/2012
1	Adrenocorticotropic Hormone (ACTH)FDA Link 03/2012
1	Mitochondrial DNA (mtDNA)IBA 02/2011
1	Lactic Acid (Lactate)FDA LinkGeneric 02/2011
1	Messenger RNA (mRNA)IBA 02/2011
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2011
1	Metformin (Glucophage)FDA LinkGeneric 01/2011
1	Cytochromes c (Cytochrome c)IBA 06/2009
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 06/2009
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2009
1	alpha- cyano- (3,4- dihydroxy)- N- benzylcinnamideIBA 01/2009

Therapy/Procedure

4	Therapeutics 01/2020 - 08/2010
1	Renal Dialysis (Hemodialysis) 01/2020
1	Renal Replacement Therapy (Therapies, Renal Replacement) 05/2019
1	Length of Stay 05/2019
1	Intravenous Administration 01/2018